advertisement
Abstract #24647 Published in IGR 11-4
Treatment persistency of xalatan-xalacom, lumigan ganfort and travatan-duotrav: An analysis conducted on the United-Kingdom general practitioner research database
Berdeaux G; Lafuma A; Robert JValue in Health 2009; 12: A452
OBJECTIVES: The objective of this analysis was to compare treatment persistency of three treatment sequences: Xalatan-Xalacom (XX), Lumigan-Ganfort (LG) and Travatan-DuoTrav (TD) according to data collected in the United-Kingdom General Practitioner Research Database (UK-GPRD). METHODS: Patients with a diagnosis of ocular hypertension or glaucoma, or treated with a topical treatment, surgery or laser were selected. Patients with sequence prescription of XX, LG and TD were selected. A treatment failure was defined as a prescription change (adding or removing a topical treatment). Time to treatment failure was compared using Wilcoxon test applied to survival curves. Adjustment on confounding variables was performed with the propensity score method using a logistic stepwise regression. RESULTS: 1562 patients were treated by XX, 110 by LG and 114 by TD. Mean age was 75 years and the sex-ratio was close to 1 male/ 1 female. No demographic or co-morbidity differences between treatment sequences were observed. At 30 months, 66.5% of the XX patients had not failed (remain with the same treatment sequence), versus 60.5% of the LG and 75.1% of the TD patients (Wilcoxon, P = 0.005). At 60 months these results became, 42.2%, 49.9%, and 52.0%, respectively (Wilcoxon, P = 0.04). Adjustment for confounding variables did not change these estimates. CONCLUSIONS: According to the UK-GPRD information, the Travatan-DuoTrav treatment sequence was associated with longer treatment persistence.
G. Berdeaux. Conservatoire National des Arts et Metiers, Paris, Hauts de SeineFrance.
Classification:
11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (Part of: 11 Medical treatment)
11.4 Prostaglandins (Part of: 11 Medical treatment)
